3B Blackbio DX Ltd
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
- Market Cap ₹ 531 Cr.
- Current Price ₹ 707
- High / Low ₹ 924 / 390
- Stock P/E 21.3
- Book Value ₹ 283
- Dividend Yield 0.35 %
- ROCE 10.8 %
- ROE 8.97 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 33.0% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 192%
- Promoter holding has increased by 2.86% over last quarter.
Cons
- The company has delivered a poor sales growth of -5.06% over past five years.
- Earnings include an other income of Rs.8.72 Cr.
- Company has high debtors of 417 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | 20 | 21 | 18 | 16 | 13 | 16 | 12 | 14 | 14 | 16 | 12 | 52 | |
19 | 18 | 20 | 17 | 15 | 12 | 14 | 12 | 14 | 16 | 17 | 13 | 28 | |
Operating Profit | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | -0 | -1 | -1 | -1 | 25 |
OPM % | 8% | 7% | 6% | 7% | 7% | 8% | 7% | 4% | -2% | -8% | -8% | -8% | 47% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 10 | 4 | 9 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Profit before tax | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 3 | 32 |
Tax % | 27% | 27% | 14% | 21% | 23% | 14% | 9% | 2% | 0% | 18% | 5% | 18% | |
1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 2 | 25 | |
EPS in Rs | 1.13 | 0.89 | 0.59 | 0.34 | 0.30 | 0.36 | 0.81 | 0.67 | 0.81 | 2.29 | 10.67 | 2.88 | 33.12 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 83% | 61% | 74% | 86% | 392% | 98% | 87% |
Compounded Sales Growth | |
---|---|
10 Years: | -5% |
5 Years: | -5% |
3 Years: | -4% |
TTM: | 35% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 33% |
3 Years: | 52% |
TTM: | 54% |
Stock Price CAGR | |
---|---|
10 Years: | 60% |
5 Years: | 53% |
3 Years: | 19% |
1 Year: | 63% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 13% |
3 Years: | 17% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 9 |
Reserves | 3 | 4 | 4 | 4 | 5 | 5 | 9 | 9 | 13 | 15 | 16 | 17 | 204 |
5 | 6 | 6 | 7 | 7 | 8 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | |
7 | 7 | 7 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 4 | 11 | |
Total Liabilities | 22 | 23 | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 30 | 225 |
3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 7 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 4 | 4 | 106 |
19 | 20 | 21 | 22 | 21 | 21 | 22 | 23 | 22 | 23 | 25 | 23 | 112 | |
Total Assets | 22 | 23 | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 30 | 225 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | -1 | 0 | 0 | 1 | 0 | -1 | 0 | 1 | 3 | 8 | 2 | |
-1 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -2 | -0 | -2 | -0 | |
1 | -0 | 0 | -0 | -1 | -0 | 1 | -0 | 1 | -2 | -6 | -3 | |
Net Cash Flow | 1 | -1 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 1 | 0 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 181 | 222 | 217 | 271 | 303 | 371 | 332 | 426 | 382 | 358 | 337 | 417 |
Inventory Days | 104 | 136 | 106 | 128 | 121 | 190 | 108 | 176 | 116 | 88 | 81 | 127 |
Days Payable | 160 | 204 | 175 | 204 | 190 | 237 | 115 | 156 | 108 | 95 | 108 | 88 |
Cash Conversion Cycle | 125 | 155 | 148 | 196 | 234 | 323 | 326 | 447 | 390 | 351 | 311 | 456 |
Working Capital Days | 168 | 219 | 222 | 282 | 331 | 428 | 410 | 549 | 494 | 447 | 431 | 588 |
ROCE % | 11% | 9% | 7% | 6% | 5% | 6% | 6% | 4% | 4% | 9% | 34% | 11% |
Documents
Announcements
- Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015. 1d
- Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter / Year Ended March 31, 2024 . 2 May
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 27 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 27 Apr
- Submission Of Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31-03-2024 15 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit